VB
ViroBlock develops antiviral drug candidates by targeting and inhibiting essential viral ion channels, a specific vulnerability in pathogens. The company utilizes rapid screening approaches to identify novel inhibitors against these channels, effectively curbing viral infectivity. Furthermore, their technology accurately predicts potential viral resistance mechanisms to preemptively address evolutionary strategies.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- ViroBlock develops antiviral drug candidates by targeting and inhibiting essential viral ion channels, a specific vulnerability in pathogens. The company utilizes rapid screening approaches to identify novel inhibitors against these channels, effectively curbing viral infectivity. Furthermore, their technology accurately predicts potential viral resistance mechanisms to preemptively address evolutionary strategies.